Birk Möller,Lena-Luise Becker,Afshin Saffari,Alexandra Afenjar,Emanuele G Coci,Rachel Williamson,Catherine Ward-Melver,Marc Gibaud,Lucie Sedláčková,Petra Laššuthová,Zuzana Libá,Markéta Vlčková,Nancy William,Eric W Klee,Ralitza H Gavrilova,Jonathan Lévy,Yline Capri,Mena Scavina,Robert Walter Körner,Zaheer Valuvullah,Claudia Weiß,Greta Marit Möller,Moritz Thiel,Margje Sinnema,Erik-Jan Kamsteeg,Sandra Donkervoort,Veronique Duboc,Khaoula Zaafrane-Khachnaoui,Nour Elkhateeb,Laila Selim,Henri Margot,Victor Marin,Claire Beneteau,Bertrand Isidor,Benjamin Cogne,Boris Keren,Benno Küsters,Alan H Beggs,Casie A Genetti,Joost Nicolai,Jörg Dötsch,Anne Koy,Carsten G Bönnemann,Maja von der Hagen,Jürgen-Christoph von Kleist-Retzow,Nicol Voermans,Heinz Jungbluth,Hormos Salimi Dafsari

Abstract:Intracellular trafficking involves an intricate machinery of motor complexes including the dynein complex to shuttle cargo for autophagolysosomal degradation. Deficiency in dynein axonemal chains as well as cytoplasmic light and intermediate chains have been linked with ciliary dyskinesia and skeletal dysplasia. The cytoplasmic dynein 1 heavy chain protein (DYNC1H1) serves as a core complex for retrograde trafficking in neuronal axons. Dominant pathogenic variants in DYNC1H1 have been previously implicated in peripheral neuromuscular disorders (NMD) and neurodevelopmental disorders (NDD). As heavy-chain dynein is ubiquitously expressed, the apparent selectivity of heavy-chain dyneinopathy for motor neuronal phenotypes remains currently unaccounted for. Here, we aimed to evaluate the full DYNC1H1 -related clinical, molecular and imaging spectrum, including multisystem features and novel phenotypes presenting throughout life. We identified 47 cases from 43 families with pathogenic heterozygous variants in DYNC1H1 (aged 0-59 years) and collected phenotypic data via a comprehensive standardized survey and clinical follow-up appointments. Most patients presented with divergent and previously unrecognized neurological and multisystem features, leading to significant delays in genetic testing and establishing the correct diagnosis. Neurological phenotypes include novel autonomic features, previously rarely described behavioral disorders, movement disorders, and periventricular lesions. Sensory neuropathy was identified in nine patients (median age of onset 10.6 years), of which five were only diagnosed after the second decade of life, and three had a progressive age-dependent sensory neuropathy. Novel multisystem features included primary immunodeficiency, bilateral sensorineural hearing loss, organ anomalies, and skeletal manifestations, resembling the phenotypic spectrum of other dyneinopathies. We also identified an age-dependent biphasic disease course with developmental regression in the first decade and, following a period of stability, neurodegenerative progression after the second decade of life. Of note, we observed several cases in whom neurodegeneration appeared to be prompted by intercurrent systemic infections with double-stranded DNA viruses (Herpesviridae) or single-stranded RNA viruses (Ross-River fever, SARS-CoV-2). Moreover, the disease course appeared to be exacerbated by viral infections regardless of age and/or severity of NDD manifestations, indicating a role of dynein in anti-viral immunity and neuronal health. In summary, our findings expand the clinical, imaging, and molecular spectrum of pathogenic DYNC1H1 variants beyond motor neuropathy disorders and suggest a life-long continuum and age-related progression due to deficient intracellular trafficking. This study will facilitate early diagnosis and improve counselling and health surveillance of affected patients.

Movement disorder phenotype in CTNNB1-syndrome: A complex but recognizable phenomenology

Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants

Clinical phenotypic spectrum of CTNNB1 neurodevelopmental disorder

Hyperkinetic stereotyped movements in a boy with biallelic CNTNAP2 variants

Analysis of Clinical Phenotype and CGH1 Gene Mutations in a Family Affected with Dopa-Responsive Dystonia

Novel CTNNB1 variant leading to neurodevelopmental disorder with spastic diplegia and visual defects plus peripheral neuropathy: A case report

Motor phenotypes associated with genetic neurodevelopmental disorders

Motor, epileptic, and developmental phenotypes in genetic disorders affecting G protein coupled receptors-cAMP signaling

Genetic and clinical characteristics of 24 mainland Chinese patients with <i>CTNNB1</i> loss-of-function variants

DHDDS and NUS1: A Converging Pathway and Common Phenotype

Paroxysmal Dystonic Posturing Mimicking Nocturnal Leg Cramps as a Presenting Sign in an Infant with DCC Mutation, Callosal Agenesis and Mirror Movements

The expanding clinical and genetic spectrum of DYNC1H1 -related disorders

Widening the infantile hypotonia with psychomotor retardation and characteristic Facies-1 Syndrome's clinical and molecular spectrum through NALCN in-silico structural analysis

Psychiatric phenotype in neurodevelopmental myoclonus-dystonia is underpinned by abnormality of cerebellar modulation on the cerebral cortex

Sensory–Motor Polyneuropathy in an 11-year- old Girl with a Pathogenic Variant in SMC1A: A Case Report

Expanding the Phenotypic and Genetic Spectrum of Neuromuscular Diseases Caused by DYNC1H1 Mutations

Biallelic ZBTB11 Variants: A Neurodevelopmental Condition with Progressive Complex Movement Disorders

New Phenotype of DCTN1‐related Spectrum: Early‐onset Dhmn Plus Congenital Foot Deformity

Seizure and movement disorder in CACNA1E developmental and epileptic encephalopathy: Two sides of the same coin or same side of two different coins?

Exploring the clinical spectrum of CNTNAP2-related neurodevelopmental disorders: A case series and a literature appraisal

CHD8-related disorders redefined: an expanding spectrum of dystonic phenotypes